Metabolic Engineering of Commensal Bacteria for Producing 5-Hydroxyindoleacetic Acid as a Therapeutic Strategy for Colitis
- 11 March 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (4) , 1412-1425
Abstract
Numerous studies have demonstrated a strong association between gut microbiota dysbiosis and the progression of colitis, potentially mediated by disruptions in microbial tryptophan metabolism. Targeting commensal bacterial tryptophan metabolism may offer a promising therapeutic strategy. However, a broader spectrum of active substances is necessary to diversify engineered probiotics and enhance the efficacy and precision of treatments. In this study, using a dextran sulfate sodium (DSS)-induced murine colitis model for active substance screening, we observed a significant alteration of the gut microbiota structure concurrent with a pronounced decrease in the level of the microbial-derived tryptophan metabolite, 5-hydroxyindoleacetic acid (5-HIAA). Exogenous supplementation with 5-HIAA restored intestinal epithelial barrier integrity and alleviated colitis symptoms. Mechanistically, 5-HIAA activates the aryl hydrocarbon receptor (AhR), leading to enhanced transcription of IL-10 and subsequent modulation of the NF-κB p65/MLCK/pMLC signaling pathway in intestinal epithelial cells. This cascade promotes increased expression of tight junction proteins, thereby improving intestinal barrier function and attenuating colitis. Furthermore, we engineered a facultative anaerobic commensal bacterium capable of delivering 5-HIAA directly to the gut and evaluated its efficacy in a mouse model of colitis. Our findings indicate that targeted modulation of the key microbial metabolite 5-HIAA effectively suppresses the onset and progression of colitis. The use of engineered bacteria for site-specific 5-HIAA delivery represents a novel and promising therapeutic approach for inflammatory bowel disease (IBD).Keywords
Funding Information
- National Key Research and Development Program of China (2023YFF1204500)
- National Key Research and Development Program of China (2024YFA0917100)
- National Natural Science Foundation of China (22134003)
This publication has 41 references indexed in Scilit:
- Megasphaera Elesdenii Dysregulates Colon Epithelial Homeostasis, Aggravates Colitis‐Associated TumorigenesisAdvanced Science, 2025
- The gut microbiota‐derived metabolite indole‐3‐propionic acid enhances leptin sensitivity by targeting STAT3 against diet‐induced obesityClinical and Translational Medicine, 2024
- Disturbances of the gut microbiota-derived tryptophan metabolites as key actors in vagotomy-induced mastitis in miceCell Reports, 2024
- GPR35 promotes neutrophil recruitment in response to serotonin metabolite 5-HIAACell, 2022
- Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B CellsCell Metabolism, 2020
- Gut Microbiota Regulation of Tryptophan Metabolism in Health and DiseaseCell Host & Microbe, 2018
- Lactobacillus plantarum and Its Probiotic and Food PotentialitiesProbiotics and Antimicrobial Proteins, 2017
- Brief Report: Dialister as a Microbial Marker of Disease Activity in SpondyloarthritisArthritis & Rheumatology, 2016
- Engineered bacteria as therapeutic agentsCurrent Opinion in Biotechnology, 2015
- Probiotic Bacteria Reduce Salmonella Typhimurium Intestinal Colonization by Competing for IronCell Host & Microbe, 2013